0–11 years (n = 53) | 12–18 years (n = 29) | 19 + years (n = 58) | Total (n = 140) | |
---|---|---|---|---|
Age (years)a | 6.07 ± 3.26 | 15.07 ± 2.20 | 33.62 ± 10.54 | 20.71 ± 15.64 |
Age at diagnosis (years)a | 0.83 ± 1.49 | 1.79 ± 2.66 | 10.79 ± 11.49 | 5.16 ± 8.92 |
Severity of hemophilia A | ||||
Moderate | 4% | 3% | 5% | 4% |
Severe | 96% | 97% | 95% | 96% |
Presence of inhibitors | 23% | 7% | 10% | 14% |
Presence of bone-joint conditions | 19% | 34% | 69% | 43% |
Number of target joints affectedb | ||||
One | 60% | 30% | 5% | 18% |
Two | 30% | 30% | 18% | 22% |
Three | 10% | 40% | 31% | 28% |
More than three | 0% | 0% | 49% | 32% |
Patients with bleeding registered during the last year | 43% | 34% | 48% | 44% |
Type of prophylaxisc | ||||
Primary continuous | 45% | 21% | 0% | 22% |
Secondary continuous | 21% | 31% | 12% | 19% |
Tertiary continuous | 17% | 31% | 74% | 44% |
Intermittent | 0% | 7% | 3% | 3% |
Consumption of FVIII (IU/kg/year/patient)a | 3,702 (3,135) | 3,182 (2,515) | 4,274 (4,140) | 3,819 (3,489) |